Loading
Lymphoma specialist who wrote the definitive DLBCL review and helped establish polatuzumab and other new agents.
Laurie Sehn developed the revised International Prognostic Index for the rituximab era, led the BC Cancer population-based studies that showed R-CHOP's real-world impact, and was a lead investigator of the GO29365 trial establishing polatuzumab vedotin in relapsed DLBCL and of POLARIX. She authored the 2021 NEJM review of DLBCL and chairs lymphoma care in British Columbia.
| Title | Journal | Year |
|---|---|---|
| Diffuse large B-cell lymphoma | NEJM | 2021 |
| Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma | JCO | 2020 |
A new combination for relapsed or refractory follicular lymphoma that adds a CD19-directed antibody to the established lenalidomide and rituximab pairing, with the largest progression-free survival hazard ratio reported in the setting.
A failure worth reading: the drug worked where patients could tolerate the regimen it was added to, and harmed where they could not. It is the strongest argument in lymphoma for designing first-line combinations around what an older patient can finish.
Rituximab remains the CD20 antibody used in first-line diffuse large B-cell lymphoma. The result is a warning against assuming an antibody improvement carries from one B-cell malignancy to another: the same substitution improved progression-free survival in chronic lymphocytic leukaemia and in follicular lymphoma.
Shares POLARIX, CD20, Antibody-drug conjugate (ADC), Diffuse large B-cell lymphoma and the tag lymphoma.
Shares POLARIX, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Antibody-drug conjugate (ADC) and the tag lymphoma.
Shares BC Cancer, Antibody-drug conjugate (ADC) and the tag canada.
Shares CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares Randomized phase III trial of ibrutinib and R-CHOP in non-germinal centre B-cell diffuse large B-cell lymphoma (PHOENIX), Diffuse large B-cell lymphoma and the tag lymphoma.
Shares CD20, Diffuse large B-cell lymphoma and the tag lymphoma.
Shares POLARIX, CD20, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Antibody-drug conjugate (ADC).
Shares Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Diffuse large B-cell lymphoma and the tag lymphoma.